Cambridge, MA, United States of America

Mark Kalinich

This inventor holds 4 USPTO granted patents and 1 EPO patent. Top assignees: The General Hospital Corporation, Watershed Informatics, Inc.. Active years: 2022-2025.


% Patents Active = 100.0

 

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2022-2025

Loading Chart...
Loading Chart...
4 patents (USPTO):Explore Patents

Title: Mark Kalinich: Innovator in Software Development and Cancer Research

Introduction

Mark Kalinich is a notable inventor based in Cambridge, MA (US), recognized for his contributions to software development and cancer research. He holds a total of 4 patents, showcasing his innovative approach to technology and healthcare.

Latest Patents

Kalinich's latest patents include groundbreaking techniques for visual software modification. These techniques involve generating a data model of code elements and a kernel for execution, creating an adjustable graphical user interface (GUI) form control, and modifying the subset of source code based on user input. Another significant patent focuses on digital analysis of blood samples to determine the efficacy of cancer therapies. This method analyzes RNA from circulating tumor cells and other sources to predict patient outcomes for specific anti-cancer treatments.

Career Highlights

Throughout his career, Mark Kalinich has worked with prominent organizations, including The General Hospital Corporation and Watershed Informatics, Inc. His work has significantly impacted both the fields of software development and cancer research.

Collaborations

Kalinich has collaborated with esteemed colleagues such as Daniel Arie Haber and Shyamala Maheswaran, contributing to advancements in their respective fields.

Conclusion

Mark Kalinich's innovative patents and career achievements highlight his significant contributions to technology and healthcare. His work continues to influence the development of software and cancer treatment methodologies.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…